Med-IQ
Helping Your Patients With Timely Diagnosis, Management, and Specialist Referrals for Moderate-to-Severe Atopic Dermatitis

Helping Your Patients With Timely Diagnosis, Management, and Specialist Referrals for Moderate-to-Severe Atopic Dermatitis

Webcast
Online Course | Specialties: Allergy and Immunology, Dermatology
Released: 12/14/2021
|
Expires: 12/13/2022
|
Max Credits: 0.75

By clicking "Continue," you confirm that you have reviewed the CME information.

Continue Read Overview

Faculty
Lawrence F. Eichenfield, MD
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
University of California San Diego School of Medicine
Chief, Pediatric and Adolescent Dermatology
Rady Children's Hospital
San Diego, CA

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Director, Family Medicine Residency Program
Abington Hospital-Jefferson Health
Abington, PA

Activity Planners
Sara Samuel, MSc, MPhil, MS
Clinical Content Manager
Med-IQ
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Med-IQ
Baltimore, MD

Amy Sison
Director of CME
Med-IQ
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM, CHCP
Associate Director, Education Quality and Compliance
Med-IQ
East Lansing, MI

Learning Objectives
Upon completion, participants should be able to:

  • Describe the burden of moderate-to-severe AD on patients and their families
  • Incorporate strategies to assess disease severity and treatment effectiveness into the routine care of patients with AD
  • Describe the rationale for and appropriate timing of specialty referral for patients with moderate-to-severe AD in need of step-up systemic treatment

Target Audience
This activity is intended for healthcare providers in primary care and pediatric practices, including primary care physicians, pediatricians, nurse practitioners, physician assistants, and nurses.

Statement of Need
As many as one-third of patients with atopic dermatitis (AD) have moderate-to-severe disease, which is associated with markedly reduced quality of life and overall well-being. Patients with uncontrolled moderate-to-severe AD have a major unmet treatment need, experiencing frequent cycles of flares and periods of remission. Despite the use of aggressive topical therapy, some patients with moderate-to-severe disease require a step-up approach, whereby they switch to systemic treatments or phototherapy. However, many patients receive no systemic treatment, and inadequate disease control with phototherapy or immunosuppressive therapy is common. Thus, there is a need for more effective therapies for patients with moderate-to-severe AD that can offer improved disease control and support individual patient needs.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CLAIMING MOC POINTS: If you intend to claim MOC points for your participation, you will need to provide your unique, six-digit ABIM ID Number. Please note, your name, ABIM ID number, birthdate, and completion status will be shared with ABIM through the ACCME PARS system. Your points will be automatically submitted to the ABIM on your behalf; please allow 4 weeks for your points to display on the ABIM website.

Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This nursing activity has been approved for up to 0.75 contact hour.

Physician assistants and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions to Receive Credit
To receive credit, read the introductory CE material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: December 14, 2021
Expiration Date: December 13, 2022
Estimated Time to Complete This Activity: 45 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 24 months that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Lawrence F. Eichenfield, MD
Consulting fees/advisory boards: AbbVie Inc., Almirall, Arcutis Biotherapeutics, Arena Pharmaceuticals Inc., Biotherapeutics Inc., Dermavant Sciences, Dermira, Eli Lilly and Company, Forte Pharma, Galderma Laboratories, L.P., Incyte Corporation, Novartis Pharmaceuticals Corporation, Ortho Dermatologics, Otsuka America Pharmaceutical, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
Contracted research: AbbVie Inc., Dermira, Eli Lilly and Company, Galderma Laboratories, L.P., Incyte Corporation, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Valeant Pharmaceuticals International, Inc.

John J. Russell, MD, FAAFP
Consulting fees/advisory boards: Bayer Healthcare Pharmaceuticals, GlaxoSmithKline, Sanofi-aventis U.S. Inc.
Fees received for promotional/non-CE activities: Sanofi-aventis U.S. Inc.

The peer reviewers and activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-notice.

Complimentary CE
This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and from Sanofi Genzyme and Regeneron Pharmaceuticals.

Copyrighted

Overview

PDF: Handouts

By clicking "Continue," you confirm that you have reviewed the CME information.

Continue

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.